PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
November 19, 2025Case Reports in Oncology0 citationsOpen Access

Palbociclib-Induced Lung Disease in Metastatic Breast Cancer: Clinical Insights

Palbociclib-Induced Interstitial Lung Disease in Metastatic Breast Cancer: A Case Report and Clinical Considerations

View Full Paper
Ask AI
Bookmark
Share

Authors

TCTiago Pina CabralPCPatrícia CavacoHMHelena Miranda

Discussion

Loading...

Member takes

Overview

Case report highlights toxicity of palbociclib in metastatic breast cancer, suggesting need for management guidelines and biomarker research.

Key Points

  • This case report aims to detail the occurrence and management of interstitial lung disease induced by palbociclib in a patient with metastatic breast cancer.
  • Case report of a 76-year-old woman with metastatic HR+/HER2-negative breast cancer
  • Assessment of interstitial lung disease following prolonged palbociclib exposure
  • Evaluation of treatment outcome after discontinuation of palbociclib and administration of corticosteroids.
  • The patient developed interstitial lung disease after treatment with palbociclib
  • Discontinuation of palbociclib and high-dose corticosteroids led to symptomatic and radiological improvement
  • Highlights the underrecognized toxicity of CDK 4/6 inhibitors in older patients and need for prompt diagnosis.

Cite This Study

Cabral et al. (2025) studied this question.

synapsesocial.com/papers/6924fee0c0ce034ddc351490https://doi.org/10.1159/000549439
View Full Paper
Ask AI
Bookmark
Share